U.S. House · 117th Congress · H.R. 2853
Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2021
To amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes.
Follow
Log in to follow this bill and get an email when there’s a new vote (premium).
- Sponsor
- Kurt SchraderD-OR-5
- Introduced
- April 26, 2021, in the House
- Issue areas
- Policy area
- Health (from the Congressional Research Service)
- Full text and actions
- congress.gov
Votes on this bill (0)
Neither the House nor the Senate has held a roll-call vote on this bill.
Cosponsors (0)
No member has cosponsored this bill.